Fig. 7
From: Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells
Effect of the combination of brusatol with anticancer drugs on cell proliferation and HCV infection. a Growth of the HPI cells after the administration of brusatol, the anticancer drugs or their combination (at a concentration of GI50). Cell viability was determined with the MTS assay. The cell growth rate is presented as fold change relative to that of 0 h. b qRT-PCR for the HCV RNA after the administration of brusatol, the anticancer drugs, or the combination of brusatol with the anticancer drugs (at a concentration of GI50). The value for the HCV RNA was normalized by the value for GAPDH RNA and is presented as fold change relative to the value in the absence of reagent. Statistical significance *: p < 0.01, **: p < 0.001, ***: p < 0.0001 versus the single administration of the corresponding anticancer drug